Status: Recruiting
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: University of MiamiUpdated: Dec 8, 2025Locations: 1
Eligibility criteria
Documented histologic diagnosis of relapsed or refractory glioblastoma multiform... [+11]
Females who are pregnant or lactating [+2]